[go: up one dir, main page]

CY2016036I1 - Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1 - Google Patents

Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Info

Publication number
CY2016036I1
CY2016036I1 CY2016036C CY2016036C CY2016036I1 CY 2016036 I1 CY2016036 I1 CY 2016036I1 CY 2016036 C CY2016036 C CY 2016036C CY 2016036 C CY2016036 C CY 2016036C CY 2016036 I1 CY2016036 I1 CY 2016036I1
Authority
CY
Cyprus
Prior art keywords
antibodies
treatment
methods
multiple myeloma
combination therapies
Prior art date
Application number
CY2016036C
Other languages
English (en)
Other versions
CY2016036I2 (el
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY2016036I2 publication Critical patent/CY2016036I2/el
Publication of CY2016036I1 publication Critical patent/CY2016036I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
CY2016036C 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1 CY2016036I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (2)

Publication Number Publication Date
CY2016036I2 CY2016036I2 (el) 2017-07-12
CY2016036I1 true CY2016036I1 (el) 2017-07-12

Family

ID=38831279

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20151100379T CY1116247T1 (el) 2006-08-07 2015-04-24 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY20161100817T CY1117992T1 (el) 2006-08-07 2016-08-18 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε huluc63 μαζι με bortezomib
CY2016038C CY2016038I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016036C CY2016036I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY2016037C CY2016037I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20151100379T CY1116247T1 (el) 2006-08-07 2015-04-24 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
CY20161100817T CY1117992T1 (el) 2006-08-07 2016-08-18 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε huluc63 μαζι με bortezomib
CY2016038C CY2016038I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016037C CY2016037I1 (el) 2006-08-07 2016-10-26 Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1

Country Status (23)

Country Link
US (4) US8632772B2 (el)
EP (5) EP2641600A1 (el)
JP (1) JP5340935B2 (el)
CN (1) CN101686971B (el)
AU (1) AU2007281684C1 (el)
BR (1) BRPI0716647A2 (el)
CA (1) CA2660356C (el)
CY (5) CY1116247T1 (el)
DK (2) DK2641601T3 (el)
ES (2) ES2535437T3 (el)
HR (2) HRP20150449T1 (el)
HU (4) HUE029027T2 (el)
IL (2) IL196919A (el)
LT (4) LT2641601T (el)
LU (3) LU93275I2 (el)
MX (1) MX2009001441A (el)
NL (1) NL300840I2 (el)
NO (1) NO346835B1 (el)
NZ (1) NZ574978A (el)
PL (2) PL2068874T3 (el)
PT (2) PT2641601T (el)
SI (2) SI2641601T1 (el)
WO (1) WO2008019378A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2068930E (pt) 2006-08-07 2012-10-23 Abbott Biotherapeutics Corp Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo
PL2068874T3 (pl) 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
EP2300052A4 (en) * 2008-06-16 2012-11-14 Immunogen Inc NEW SYNERGISTIC EFFECTS
EP2796134B1 (en) * 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
EP2476438B1 (en) 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
JP2013512195A (ja) * 2009-11-24 2013-04-11 セルジーン コーポレイション ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3066128B1 (en) * 2013-11-06 2018-10-31 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
SI3071597T1 (sl) 2013-11-21 2020-11-30 F. Hoffmann-La Roche Ag Anti alfa-sinukleinska protitelesa in postopki uporabe
PT3182996T (pt) 2014-08-22 2023-03-21 Celgene Corp Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
US20170355768A1 (en) * 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
MX380557B (es) 2015-05-13 2025-03-12 Morphosys Ag Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
WO2017003990A1 (en) * 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
JP2021504475A (ja) * 2017-11-22 2021-02-15 ヒルストリーム・バイオファーマ・インコーポレイテッド ボルテゾミブを含むポリマーナノ粒子
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof
CN115368462A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996037208A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2915533B1 (en) * 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2006048877A2 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies with fgfr3 inhibitors
EP2069478A2 (en) 2006-08-07 2009-06-17 PDL BioPharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
PT2068930E (pt) * 2006-08-07 2012-10-23 Abbott Biotherapeutics Corp Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo
PL2068874T3 (pl) 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1

Also Published As

Publication number Publication date
NO346835B1 (no) 2023-01-23
US8632772B2 (en) 2014-01-21
BRPI0716647A2 (pt) 2017-05-16
PT2068874E (pt) 2015-05-21
IL196919A (en) 2016-03-31
HUS1600044I1 (hu) 2016-12-28
PT2641601T (pt) 2016-10-14
LU93275I2 (fr) 2016-12-27
IL243933A0 (en) 2016-04-21
US20140322201A1 (en) 2014-10-30
CA2660356C (en) 2016-04-05
EP2641600A1 (en) 2013-09-25
ES2589302T3 (es) 2016-11-11
EP2068874A1 (en) 2009-06-17
HK1129853A1 (en) 2009-12-11
HUS1600043I1 (hu) 2016-12-28
CY2016037I1 (el) 2017-07-12
HUS1600045I1 (hu) 2016-12-28
IL196919A0 (en) 2009-11-18
CN101686971B (zh) 2013-09-11
LTPA2016031I1 (lt) 2016-11-10
MX2009001441A (es) 2009-07-06
US20080152646A1 (en) 2008-06-26
EP2068874B1 (en) 2015-01-28
NL300840I2 (el) 2017-01-03
WO2008019378A1 (en) 2008-02-14
HRP20150449T1 (xx) 2015-06-05
CY1116247T1 (el) 2017-02-08
LTPA2016029I1 (lt) 2016-11-10
DK2641601T3 (en) 2016-08-22
EP2641601B1 (en) 2016-07-06
DK2068874T3 (da) 2015-04-27
EP2942057A1 (en) 2015-11-11
CY1117992T1 (el) 2017-05-17
LU93277I2 (fr) 2016-12-27
PL2068874T3 (pl) 2015-06-30
EP2641601B8 (en) 2016-09-21
LU93276I2 (fr) 2016-12-27
ES2535437T3 (es) 2015-05-11
EP3115049A1 (en) 2017-01-11
NZ574978A (en) 2012-08-31
LT2641601T (lt) 2016-10-10
JP5340935B2 (ja) 2013-11-13
AU2007281684C1 (en) 2013-12-19
HRP20161284T1 (hr) 2016-12-16
LTPA2016030I1 (lt) 2016-11-10
US20160137735A1 (en) 2016-05-19
SI2068874T1 (sl) 2015-06-30
LTC2068874I2 (lt) 2018-11-12
SI2641601T1 (sl) 2016-11-30
EP2641601A1 (en) 2013-09-25
CY2016036I2 (el) 2017-07-12
CN101686971A (zh) 2010-03-31
PL2641601T3 (pl) 2017-01-31
AU2007281684A1 (en) 2008-02-14
NO20090968L (no) 2009-04-30
US20170342150A1 (en) 2017-11-30
JP2010500371A (ja) 2010-01-07
AU2007281684B2 (en) 2013-05-16
CY2016038I1 (el) 2017-07-12
HUE029027T2 (en) 2017-01-30
CA2660356A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
CY2016036I1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
NO344963B1 (no) Humanisert antistoff
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
CR20170001A (es) Anticuerpos anti factor d humanizados
DK2182983T3 (da) Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
BRPI0809677A2 (pt) Anticorpos anti-ige
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
LTC2330892I2 (lt) Gydymo būdai panaudojant vaistus - amoniako gaudykles
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
EP2084185A4 (en) HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer